Reuters logo
BRIEF-Biocon reaffrims guidance of $200 mln in revenue from biosimilars in FY19
March 14, 2017 / 10:07 AM / 6 months ago

BRIEF-Biocon reaffrims guidance of $200 mln in revenue from biosimilars in FY19

March 14 (Reuters) - Biocon Ltd

* Says reaffrims guidance of US $200 million in revenue from biosimilars in FY19 Source text - (bit.ly/2nztIMx) Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below